Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Nov 23, 2012

NEW YORK (GenomeWeb News) – Saladax Biomedical has appointed Mark Myslinski to the posts of senior VP and chief commercial officer. Myslinski recently was president and CEO of RedPath Integrated Pathology, where he helped to move the company from research and development to commercialization of a molecular diagnostic assay in a CLIA lab. He also has served as VP of evidence-based medicine at Ortho Clinical Diagnostics and as GM of molecular and cellular diagnostics at Veridex.

Trovagene said this week that Life Technologies' Chief Medical Officer Paul Billings has joined the Trovagene scientific advisory board.

Billings has experience as a physician, executive, and as a researcher, and he currently serves on the US Food and Drug Administration's Scientific Advisory Board, on the Genomic Medicine Advisory Committee at the Department of Veterans Affairs, and on the National Academy of Sciences Institute of Medicine's Roundtable on Genomics. He also formerly was director and chief scientific officer at the Genomic Medicine Institute at El Camino Hospital, senior VP for corporate development at LabCorp, and CEO of Cellective Dx.

As part of a corporate realignment announced this week by Sigma-Aldrich, the company said that Gerrit van den Dool will shift from his current post as managing director of the North American region to become managing director of the European region, and Jason Apter will transition from his job as chief of staff to become managing director of the Asia Pacific region. Van den Dool will relocate to Switzerland and Apter will relocate to Singapore, the company said.

Giles Cottier will continue to head the SAFC business, which will be renamed the SAFC Commercial Markets business.

As GenomeWeb Daily News reported earlier this week, Frank Wicks will now serve as president of the Applied Markets unit, and Eric Green will become president of the Research Markets business unit.

Pacific Biomarkers has hired Maribeth Raines to be VP of laboratory services. Raines recently was director of scientific affairs for Quest Diagnostics Clinical Trials, where she helped the company expand its biomarker testing services into emerging markets. She also previously was director of research and development at both Nichols Institute Diagnostics and Biosource International, and she was a faculty member at the University of California, Los Angeles School of Medicine.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.